Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477880 · ClinicalTrials.gov registry record · Phase 1
Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00477880: Completed Phase 1 study, sponsored by Vanderbilt University.
NCT00477880 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00477880, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This clinical trial is studying how well cetuximab works in treating patients with Ménétrier disease at high risk of developing stomach cancer.
Interventions
- BIOLOGICAL Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2001-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
What the finished NCT00477880 record still lists
NCT00477880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Cetuximab is the first listed.
NCT00477880 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00477880 about?
NCT00477880 is a clinical study titled "Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer". RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This clinical trial is studying how well cetuximab ...
What is the current status of trial NCT00477880?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2001-04. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00477880?
The interventions under investigation include: Cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00477880?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00477880's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia